Juno Therapeutics Expands Cell Therapy Manufacturing Capability

February 16, 2015
BioPharm International Editors

Juno's new manufacturing facility in Washington state will support clinical trials for immunotherapies.

Juno Therapeutics announced on Feb. 9, 2015 that it has entered into a lease agreement for a facility in Bothell, Washington to manufacture the company's cell-therapy products. The facility, which is expected to come online in early 2016, will support Juno's planned JCAR015 multicenter clinical trial, additional clinical programs in Juno's pipeline, and the company's first commercial products.

"The Bothell manufacturing facility is an important milestone for Juno," said Hans Bishop, CEO and president of Juno, in a press release. "The manufacturing expertise we are developing is key to our long-term success, increasing our ability to run multiple clinical trials and commercialize our pipeline, and as a platform to introduce the various innovations we are investing in to optimize patient outcomes."

Juno will continue to work with its existing contract manufacturing partners to augment its manufacturing capabilities. Among other advantages, this will enhance flexibility, provide redundancy, and increase capacity in a cost-effective manner.

Source: Juno Therapeutics